EWI-F, also known as PTGFRN, is inversely related to the loss of CD9. Its expression correlates with the metastatic status of hLT (n=55). EWI-F inhibits the binding of prostaglandin F2-alpha (PGF2-alpha) to its specific FP receptor, by decreasing the receptor number rather than the affinity constant. EWI-F expression positively correlates with the metastatic status of hLT, and that the upregulation of EWI-F expression could be one of the mechanisms underlying the loss of CD9 in solid tumours.
prostaglandin F2 receptor inhibitor
- Stipp C S. et al., 2001, J Biol Chem. 276 (7): 4853-62.
- Charrin S. et al., 2001, J Biol Chem. 276 (17): 14329-37.
- Orlicky DJ. et al., 1996, Hum Genet. 97 (5): 655-8.